EUVIMEDEUVIMED entdecken
Multizentrische Studie

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Francois-Xavier Mahon iD, Markus Pfirrmann iD, Stéphanie Dulucq iD, Andreas Hochhaus iD, Panayiotis Panayiotidis, Antonio Almeida iD, Jiri Mayer iD, Henrik Hjorth-Hansen iD, Jeroen J W M Janssen, Satu Mustjoki iD, Joaquin Martinez-Lopez iD, Hanne Vestergaard und 17 weitere

Journal of Clinical Oncology · 01.06.2024 · 42 (16) · 1875-1880

DOI: 10.1200/jco.23.01647 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2024. Verfasst von Francois-Xavier Mahon und 28 weiteren Autor:innen. Beteiligte Einrichtung: Bergonié Cancer Institute, INSERM UMR1312 Inserm, University of Bordeaux, Bordeaux, France. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Remission Induction. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsRemission InductionHumansFemaleMiddle AgedMaleAdultAgedPrognosisImatinib MesylateFusion Proteins, bcr-ablPyrimidinesEuropeYoung AdultAged, 80 and overTreatment OutcomeTyrosine Kinase Inhibitors

Substanzen

Protein Kinase InhibitorsImatinib MesylateFusion Proteins, bcr-ablPyrimidinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Bergonié Cancer Institute, INSERM UMR1312 Inserm, University of Bordeaux, Bordeaux, France.
  • Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, LMU München, München, Germany.
  • Laboratory of Hematology, University Hospital of Bordeaux, Hôpital Haut Lévêque, Pessac, France.
  • Groupe Fi-LMC, Centre Léon Bérard, Lyon, France.
  • Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
  • Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Francois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, Andreas Hochhaus, Antonio Almeida, Jiri Mayer, Henrik Hjorth-Hansen, Satu Mustjoki, Joaquin Martinez-Lopez, Hans Ehrencrona, Marc G Berger, Gabriel Etienne, Tim H Brümmendorf, Andreas Burchert, Delphine Réa, Susanne Saussele

Zitieren

APA

Mahon, F. X., Pfirrmann, M., Dulucq, S., Hochhaus, A., Panayiotidis, P., Almeida, A., Mayer, J., Hjorth-Hansen, H., Janssen, J. J. W. M., Mustjoki, S., Martinez-Lopez, J., Vestergaard, H., Ehrencrona, H., Machová Poláková, K., Olsson-Strömberg, U., Ossenkoppele, G., Berger, M. G., Etienne, G., Dengler, J., …, & Investigators (2024). European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Journal of Clinical Oncology, 42(16), 1875-1880. https://doi.org/10.1200/jco.23.01647

Vancouver

Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Journal of Clinical Oncology. 2024;42(16):1875-1880. doi:10.1200/jco.23.01647

BibTeX
@article{Mahon2024,
  author = {Mahon, Francois-Xavier and Pfirrmann, Markus and Dulucq, Stéphanie and Hochhaus, Andreas and Panayiotidis, Panayiotis and Almeida, Antonio and Mayer, Jiri and Hjorth-Hansen, Henrik and Janssen, Jeroen J W M and Mustjoki, Satu and Martinez-Lopez, Joaquin and Vestergaard, Hanne and Ehrencrona, Hans and Machová Poláková, Katerina and Olsson-Strömberg, Ulla and Ossenkoppele, Gert and Berger, Marc G and Etienne, Gabriel and Dengler, Jolanta and Brümmendorf, Tim H and Burchert, Andreas and Réa, Delphine and Rousselot, Philippe and Nicolini, Franck E and Hofmann, Wolf-Karsten and Richter, Johan and Saussele, Susanne and EURO-SKI Investigators, EURO-SKI Investigators and Investigators, Investigators},
  title = {European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {16},
  pages = {1875--1880},
  doi = {10.1200/jco.23.01647}
}
Kostenlos starten →